Berlin-based femtech startup Inne is coming out of stealth to announce an €8 million (~$8.8M) Series A and give the first glimpse of a hormone-tracking subscription product for fertility-tracking and natural contraception that’s slated for launch in Q1 next year.
The Series A is led by led by Blossom Capital, with early Inne backer Monkfish Equity also participating, along with a number of angel investors — including Taavet Hinrikus, co-founder of TransferWise; Tom Stafford, managing partner at DST; and Trivago co-founder Rolf Schromgens.
Women’s health apps have been having a tech-fuelled moment in recent years, with the rise of a femtech category. There are now all sorts of apps for tracking periods and the menstrual cycle, such as Clue and Flo.
Some also try to predict which days a women is fertile and which they’re not — offering digital tools to help women track bodily signals if they’re following a natural family planning method of contraception, or indeed tryi ..
Support the originator by clicking the read the rest link below.
